2Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, United States.

1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.

Towlerton 1 Shreeram Akilesh 1,2 Chris P. The data obtained may be relevant to future clinical studies in the setting of immunotherapy for NPC patients.Ĭlonotypes Nasopharyngeal carcinoma Prognosis TCR repertoire Vβ gene.Yuexin Xu 1* Alicia J. In conclusion, we here report the systematic and overall characteristics of the TCR repertoire in tumors, adjacent normal tissues, and peripheral blood of NPC patients.

We identified 11 clonotypes shared by tumors and peripheral blood samples from different NPC patients, defined as 'NPC-associated' that might have value in adoptive immunotherapy. Due to the peculiarity of the Vβ gene usage patterns in the peripheral blood of NPC patients, 15 Vβ genes were selected to distinguish NPC patients from controls by the least absolute shrinkage and selection operator analysis. Higher diversity in peripheral blood of NPC patients was associated with a worse prognosis. A more diverse TCR repertoire was identified in the peripheral blood of NPC patients relative to the controls this was related to a significant decrease in the proportion of high-frequency TCR clones in NPC. We found that a lower diversity of TCR repertoire in tumors than paired tissues or a low similarity between the paired tissues was associated with a poor prognosis in NPC. We performed deep sequencing for TCR repertoire profiling on matched tumor/adjacent normal tissue from 15 NPC patients and peripheral blood from 39 NPC patients, 39 patients with other nasopharyngeal diseases, and 33 healthy controls. However, the distribution characteristics of T cells associated with NPC pathogenesis are largely unknown. T-cell immune responses in nasopharyngeal carcinoma patients have been extensively investigated recently for designing adoptive immunotherapy or immune checkpoint blockade therapy. 8 Otolaryngology Head and Neck Surgery, Foshan Hospital, Sun Yat-sen University, Foshan, 528000, Guangdong, China. 7 Head and Neck Cancer Research, Department of Otolaryngology-Head and Neck Surgery, Foshan Hospital, Sun Yat-sen University, #81, North of Lingnan Ave, Foshan, 528000, Guangdong, China.1 Foshan Hospital, Clinical Research Institute, Sun Yat-sen University, #81, North of Lingnan Ave, Foshan, 528000, Guangdong, China. 6 Otolaryngology Head and Neck Surgery, Foshan Hospital, Sun Yat-sen University, Foshan, 528000, Guangdong, China.

5 Cancer Center, Foshan Hospital, Sun Yat-sen University, Foshan, 528000, Guangdong, China. 4 Head and Neck Cancer Research, Department of Otolaryngology-Head and Neck Surgery, Foshan Hospital, Sun Yat-sen University, #81, North of Lingnan Ave, Foshan, 528000, Guangdong, China.

3 Foshan Hospital, Clinical Research Institute, Sun Yat-sen University, #81, North of Lingnan Ave, Foshan, 528000, Guangdong, China.2 Head and Neck Cancer Research, Department of Otolaryngology-Head and Neck Surgery, Foshan Hospital, Sun Yat-sen University, #81, North of Lingnan Ave, Foshan, 528000, Guangdong, China.1 Foshan Hospital, Clinical Research Institute, Sun Yat-sen University, #81, North of Lingnan Ave, Foshan, 528000, Guangdong, China.

Tcr repertoire profiling